The Mycobacterium avium Infections drugs in development market research report provides comprehensive information on the therapeutics under development for Mycobacterium avium Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Mycobacterium avium Infections. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Mycobacterium avium Infections and features dormant and discontinued products.
GlobalData tracks 13 drugs in development for Mycobacterium avium Infections by 12 companies/universities/institutes. The top development phase for Mycobacterium avium Infections is discovery with five drugs in that stage. The Mycobacterium avium Infections pipeline has 12 drugs in development by companies and one by universities/ institutes. Some of the companies in the Mycobacterium avium Infections pipeline products market are: AGILeBiotics, Brii Biosciences and AN2 Therapeutics.
The key targets in the Mycobacterium avium Infections pipeline products market include 30S Ribosomal Subunit (30S RNA), 16S Ribosomal RNA (16S rRNA), and DNA Topoisomerase IV (EC 5.99.1.3).
The key mechanisms of action in the Mycobacterium avium Infections pipeline product include 30S Ribosomal Subunit (30S RNA) Inhibitor with one drug in Discovery. The Mycobacterium avium Infections pipeline products include five routes of administration with the top ROA being Inhalational and four key molecule types in the Mycobacterium avium Infections pipeline products market including Small Molecule, and Recombinant Vector Vaccine.
Mycobacterium avium Infections overview
Mycobacterium avium Infections is the most common cause of nontuberculosis mycobacterial species infections in humans, and the respiratory system is the most common site of infection. It consists of multiple nontuberculosis mycobacterial species (NTM). It is considered an opportunistic infection most observed in immunocompromised ones. It is caused by a group of bacteria most common species is M. avium and its sub-species. The mode of infection is inhalational route, ingestion through gastrointestinal. Commonly seen in those with low CD4 count, HIV patients, and a risk factor in respiratory infections like pneumonia, TB, and COPD. Symptoms range from one individual to another from chronic cough, cold, chills and fever, and hemoptysis. Diagnosis is done by CT scan and chest X-ray. Antibiotics are primary medicines targeted in MAV patients followed by symptomatic treatment. Common antibiotics are macrolides, anti-TB drugs rifampicin, ethambutol, aminoglycosides, etc. Combination therapy in severe conditions.
For a complete picture of Mycobacterium avium Infections’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
